In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Omeros, with a price target of $9.00. The company’s shares closed last Friday at $3.65.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Trevi Therapeutics, and Eupraxia Pharmaceuticals. According to TipRanks, Folkes has an average return of -6.7% and a 34.25% success rate on recommended stocks.
Currently, the analyst consensus on Omeros is a Moderate Buy with an average price target of $9.00.
The company has a one-year high of $13.60 and a one-year low of $2.95. Currently, Omeros has an average volume of 1M.
Read More on OMER:
- Omeros submission adds another 2026 catalyst, says H.C. Wainwright
- Omeros submits narsoplimab marketing authorization application to the EMA
- Omeros initiated with a Buy at H.C. Wainwright
- Omeros Corp. Earnings Call: Cautious Optimism Amid Challenges
- Omeros Corporation Reports Q1 2025 Financial Results